Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Büşra Göynük"'
Autor:
Mike Broeders, Kasper Smits, Busra Goynuk, Esmee Oussoren, Hannerieke J.M.P. van den Hout, Atze J. Bergsma, Ans T. van der Ploeg, W.W.M. Pim Pijnappel
Publikováno v:
Molecular Therapy: Methods & Clinical Development, Vol 19, Iss , Pp 174-185 (2020)
Identification and characterization of disease-associated variants in monogenic disorders is an important aspect of diagnosis, genetic counseling, prediction of disease severity, and development of therapy. However, the effects of disease-associated
Externí odkaz:
https://doaj.org/article/aa2096434c614e02b965124eabcdc167
Autor:
Jim Middelburg, Marjolein Sluijter, Gaby Schaap, Büşra Göynük, Katy Lloyd, Vitalijs Ovcinnikovs, Gijs G. Zom, Renoud J. Marijnissen, Christianne Groeneveldt, Lisa Griffioen, Gerwin G. W. Sandker, Sandra Heskamp, Sjoerd H. van der Burg, Tsolere Arakelian, Ferry Ossendorp, Ramon Arens, Janine Schuurman, Kristel Kemper, Thorbald van Hall
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-15 (2024)
Abstract CD3 bispecific antibody (CD3 bsAb) therapy is clinically approved for refractory hematological malignancies, but responses in solid tumors have been limited so far. One of the main hurdles in solid tumors is the lack of sufficient T-cell inf
Externí odkaz:
https://doaj.org/article/36795cab2cda485e96053669065dc63a
Autor:
Jim Middelburg, Marjolein Sluijter, Gaby Schaap, Büşra Göynük, Katy Lloyd, Vitalijs Ovcinnikovs, Gijs Zom, Renoud Marijnissen, Gerwin Sandker, Sandra Heskamp, Sjoerd van den Burg, Tsolere Arakelian, Ferry Ossendorp, Ramon Arens, Janine Schuurman, Kristel Kemper, Thorbald van Hall
CD3 bispecific antibody (CD3 bsAb) therapy is clinically approved for refractory hematological malignancies, but responses in solid tumors have been limited so far. One of the main hurdles in solid tumors is the lack of sufficient T-cell infiltrate.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::53efff7a4d0e88f729b064b35ec9c84b
https://doi.org/10.21203/rs.3.rs-2470572/v1
https://doi.org/10.21203/rs.3.rs-2470572/v1
Autor:
Jim Middelburg, Soroush Ghaffari, Tom A.W. Schoufour, Marjolein Sluijter, Gaby Schaap, Büsra Göynük, Benedetta M. Sala, Lejla Al-Tamimi, Ferenc Scheeren, Kees L.M.C. Franken, Jimmy J.L.L. Akkermans, Birol Cabukusta, Simone A. Joosten, Ian Derksen, Jacques Neefjes, Sjoerd H. van der Burg, Adnane Achour, Ruud H.M. Wijdeven, Jon Weidanz, Thorbald van Hall
Publikováno v:
Cell Reports, Vol 42, Iss 12, Pp 113516- (2023)
Summary: The immune checkpoint NKG2A/CD94 is a promising target for cancer immunotherapy, and its ligand major histocompatibility complex E (MHC-E) is frequently upregulated in cancer. NKG2A/CD94-mediated inhibition of lymphocytes depends on the pres
Externí odkaz:
https://doaj.org/article/380d9d0a2508416bb76695633b6aeefe